Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 40

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 40
---
 is received less than 48 hours before the vote, or less than the period
of time before the vote set by the company at its discretion.

We believe the risk of proxies
not being counted, and thus being unable to cast their votes, is low because the Australian market practice is to timely request a poll
voting at shareholders meeting. In particular, the ASX in its Guidance Note 35 has indicated that, as a matter of proper governance, all
resolutions required under the ASX listing rules must be decided by a poll rather than a show of hands. Further, Recommendation 6.4 of
the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations (4th edition) provides that all substantive
resolutions should be decided by a poll rather than a show of hands. In this regard, all resolutions at Radiopharm’s most recent
annual general meeting were decided by a poll. However, there is a possibility that, in the case of a show of hands voting, proxies representing
the majority of the voting ordinary shares may not be counted. Thus, there is a risk that shareholders resolutions are approved only by
a minority of the voting ordinary shares outstanding without regard to the interests of the majority of the voting ordinary shares.

Item 4. Information
on the Company

A. History and Development of the Company

Our legal name is Radiopharm
Theranostics Limited which was incorporated in Australia in February 2021. Our ordinary shares have been listed on the ASX under the symbol
“ RAD” since November 2021.

In July 2021, we entered into
an exclusive license agreement with NanoMab Technologies Limited (“ NanoMab”). Under the terms of the agreement, we have the
exclusive rights to the technology NanoMab developed, and in particular Anti-HER-2, Anti-TROP-2, Anti-PD-L1 and Anti-PTK7. We have agreed
to pay certain upfront license fees and performance-based consideration linked to the achievement of certain value-inflection development
milestones and commercial outcomes, as well as net sales-based royalty payments and sublicensing fees.

In July 2021, we entered into
an exclusive license agreement with TRIMT GmbH (“ TRIMT”). Under the terms of the agreement, we have exclusive rights to the
Ga-Trivehexin technology TRIMT developed. We have agreed to pay upfront license fees equivalent to US$10 million in the form of cash and
shares, and